Breaking News Instant updates and real-time market news.

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

07:27
10/23/17
10/23
07:27
10/23/17
07:27

Barclays cuts DBV target to $30, thinks FDA approval still warranted

Barclays analyst Geoff Meacham lowered his price target for DBV Technologies to $30 citing the negative Phase 3 trial of Viaskin Peanut. While the difference in responder rates was statistically significant, "highly robust and we think clinically meaningful," trial formally missed the statistical threshold for success, Meacham tells investors in a research note. The "clean" safety profile of Viaskin Peanut combined with efficacy data that show a clear clinical benefit in a major unmet need should warrant FDA approval, the analyst contends. His new price target, however, reflects lower commercial potential and a lower probability of success for DBV's earlier stage assets. Meacham keeps an Overweight rating on the shares.

DBVT DBV Technologies
$48.07

0.92 (1.95%)

10/12/17
SBSH
10/12/17
NO CHANGE
Target $57
SBSH
Buy
DBV news today does not impact timelines for efficacy study, says Citi
Citi analyst Liav Abraham says she confirmed with management of DBV Technologies that today's announcement regarding the Realise study has no bearing on the timelines for readout of the pivotal efficacy study for Viaksin Peanut, the Pepites study, which remains on track for a headline data readout this month. The analyst remains "constructive" on the shares ahead of the Pepites data readout in October. She notes that Realise is DBV's second Phase III study for Viaskin Peanut, and is a safety study, unlike Pepites, which is an efficacy study. Abraham has a Buy rating on DBV with a $57 price target.
10/20/17
PIPR
10/20/17
NO CHANGE
Target $38
PIPR
Overweight
Piper sees ' increasingly favorable' risk/reward for Aimmune Phase III program
After hosting investor meetings with management, Piper Jaffray analyst Charles Duncan sees an "increasingly favorable" risk/reward for Aimmune Therapeutics' (AIMT) AR101 Phase III peanut allergy program heading into the clinical progress results in Q1 of 2018. Aimmune has a "best-in-class" approach to peanut allergy immunotherapy which can address at least 25%-40%) of the moderate to severe peanut allergic market, Duncan tells investors in a research note. The analyst believes some volatility in the shares is possible around the near-term Phase III Pepites results from "mind-share competitor" DBV Technologies (DBVT). Duncan views Aimmune as undervalued and keeps an Overweight rating on the shares with a $38 price target.
10/23/17
JEFF
10/23/17
NO CHANGE
Target $37
JEFF
Buy
Jefferies still sees greater than 50% odds for DBV approval
Jefferies analyst Eun Yang believes DBV Technologies' Viaskin Peanut has greater than 50/50 odds of FDA approval even though the Phase III study missed the lower bound of proposed efficacy range. The analyst highlights the statistically significant Phase 3 data, "likely clinically meaningful tolerance" of three peanuts on Viaskin Peanut versus one peanut on placebo, and potential improved response over time. The analyst lowered her price target for DBV shares to $37 from $51 and keeps a Buy rating on the name. The stock in premarket trading is down 44% to $26.80.
10/23/17
WEDB
10/23/17
NO CHANGE
Target $70
WEDB
Outperform
Aimmune price target raised to $70 from $42 at Wedbush
Wedbush analyst Liana Moussatos raised her price target for Aimmune (AIMT) to $70 from $42, while reiterating an Outperform rating on the shares. Following the failure of DBV Technologies' (DBVT) Viaskin-peanut to achieve the FDA's minimum of 15% better efficacy than placebo as a minimum measure of clinical meaningfulness, the analyst anticipates FDA is likely to require another Phase 3 trial, which reduces competition risk.

TODAY'S FREE FLY STORIES

CYD

China Yuchai

$24.85

0.27 (1.10%)

06:04
11/22/17
11/22
06:04
11/22/17
06:04
Hot Stocks
China Yuchai receives first order from BAIC Group for passenger vehicle engines »

China Yuchai announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KW

Kennedy Wilson

$19.40

0.3 (1.57%)

06:02
11/22/17
11/22
06:02
11/22/17
06:02
Hot Stocks
Kennedy Wilson acquires apartment community in Greater Bellevue for $135M »

Kennedy Wilson has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KBR

KBR

$18.85

0.23 (1.24%)

05:55
11/22/17
11/22
05:55
11/22/17
05:55
Hot Stocks
KBR JV awarded FEED contract for Absheron Field in Azerbaijan »

KBR announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

CRM

Salesforce

$108.80

1.43 (1.33%)

05:52
11/22/17
11/22
05:52
11/22/17
05:52
Downgrade
Salesforce rating change  »

Salesforce downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

GG

Goldcorp

$13.23

-0.05 (-0.38%)

05:49
11/22/17
11/22
05:49
11/22/17
05:49
Downgrade
Goldcorp rating change  »

Goldcorp downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRNO

Terreno Realty

$37.74

0.74 (2.00%)

05:46
11/22/17
11/22
05:46
11/22/17
05:46
Upgrade
Terreno Realty rating change  »

Terreno Realty upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

PAAS

Pan American Silver

$15.20

0.22 (1.47%)

05:42
11/22/17
11/22
05:42
11/22/17
05:42
Upgrade
Pan American Silver rating change  »

Pan American Silver…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 05

    Dec

CBRL

Cracker Barrel

$150.79

-6.41 (-4.08%)

05:41
11/22/17
11/22
05:41
11/22/17
05:41
Downgrade
Cracker Barrel rating change  »

Cracker Barrel downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIPS

Vipshop

$8.22

-1.03 (-11.14%)

05:39
11/22/17
11/22
05:39
11/22/17
05:39
Recommendations
Vipshop analyst commentary  »

Vipshop price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NJR

New Jersey Resources

$43.80

-0.5 (-1.13%)

05:35
11/22/17
11/22
05:35
11/22/17
05:35
Upgrade
New Jersey Resources rating change  »

New Jersey Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBPB

Potbelly

$12.15

-0.15 (-1.22%)

05:31
11/22/17
11/22
05:31
11/22/17
05:31
Recommendations
Potbelly analyst commentary  »

Potbelly shares remain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$108.80

1.43 (1.33%)

05:29
11/22/17
11/22
05:29
11/22/17
05:29
Recommendations
Salesforce analyst commentary  »

Salesforce price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

YNDX

Yandex

$34.28

0.57 (1.69%)

05:28
11/22/17
11/22
05:28
11/22/17
05:28
Hot Stocks
Yandex appoints Greg Abovsky as COO »

Yandex announced changes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNK

Mallinckrodt

$21.39

-0.42 (-1.93%)

05:26
11/22/17
11/22
05:26
11/22/17
05:26
Downgrade
Mallinckrodt rating change  »

Mallinckrodt downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

05:25
11/22/17
11/22
05:25
11/22/17
05:25
General news
FX Action: The dollar has perked up »

FX Action: The dollar…

SIG

Signet Jewelers

$52.79

-23.05 (-30.39%)

05:22
11/22/17
11/22
05:22
11/22/17
05:22
Recommendations
Signet Jewelers analyst commentary  »

Signet Jewelers price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

AXTA

Axalta Coating

$33.87

0.33 (0.98%)

05:19
11/22/17
11/22
05:19
11/22/17
05:19
Recommendations
Axalta Coating analyst commentary  »

Nippon could bid as much…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXTA

Axalta Coating

$33.87

0.33 (0.98%)

, AKZOY

AkzoNobel

$30.57

0.085 (0.28%)

05:16
11/22/17
11/22
05:16
11/22/17
05:16
Hot Stocks
Axalta Coating confirms takeover talks with Nippon Paint »

Axalta Coating Systems…

AXTA

Axalta Coating

$33.87

0.33 (0.98%)

AKZOY

AkzoNobel

$30.57

0.085 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RLOG

Rand Logistics

$0.59

0.016 (2.80%)

05:15
11/22/17
11/22
05:15
11/22/17
05:15
Hot Stocks
Rand Logistics to be acquired by American Industrial Partners »

Rand Logistics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGMS

Scientific Games

$52.20

-0.3 (-0.57%)

05:12
11/22/17
11/22
05:12
11/22/17
05:12
Hot Stocks
Scientific Games acquires 11.6M ordinary shares of NYX Gaming »

Scientific Games…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADI

Analog Devices

$90.19

-2.88 (-3.09%)

05:12
11/22/17
11/22
05:12
11/22/17
05:12
Recommendations
Analog Devices analyst commentary  »

Analog Devices price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

TEDU

Tarena

$13.36

-2.53 (-15.92%)

05:10
11/22/17
11/22
05:10
11/22/17
05:10
Downgrade
Tarena rating change  »

Tarena downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$22.46

0.34 (1.54%)

05:07
11/22/17
11/22
05:07
11/22/17
05:07
Recommendations
HP Inc. analyst commentary  »

HP Inc. target raised to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$108.80

1.43 (1.33%)

05:05
11/22/17
11/22
05:05
11/22/17
05:05
Recommendations
Salesforce analyst commentary  »

Salesforce price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

AXTA

Axalta Coating

$33.87

0.33 (0.98%)

, AKZOY

AkzoNobel

$30.57

0.085 (0.28%)

05:03
11/22/17
11/22
05:03
11/22/17
05:03
Recommendations
Axalta Coating, AkzoNobel, Berkshire Hathaway, Berkshire Hathaway analyst commentary  »

Axalta remains potential…

AXTA

Axalta Coating

$33.87

0.33 (0.98%)

AKZOY

AkzoNobel

$30.57

0.085 (0.28%)

BRK.A

Berkshire Hathaway

$275,000.00

2995 (1.10%)

BRK.B

Berkshire Hathaway

$183.18

1.55 (0.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.